Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children

References

• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27:Suppl 2 B51 - 63; http://dx.doi.org/10.1016/j.vaccine.2009.04.063; PMID: 19477562
   PubMed Web of Science ®Google Scholar
• Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine 2006; 24:4692 - 700; http://dx.doi.org/10.1016/j.vaccine.2006.03.034; PMID: 16621189
   PubMed Web of Science ®Google Scholar
• Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006; 19:142 - 64; PMID: 16418528
   PubMed Web of Science ®Google Scholar
• Bröker M, Veitch K. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine. Travel Med Infect Dis 2010; 8:47 - 50; http://dx.doi.org/10.1016/j.tmaid.2009.12.001; PMID: 20188306
   PubMedGoogle Scholar
• Borrow R, Miller E. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev Vaccines 2006; 5:851 - 7; http://dx.doi.org/10.1586/14760584.5.6.851; PMID: 17184222
   PubMed Web of Science ®Google Scholar
• Knuf M, Kieninger-Baum D, Habermehl P, Muttonen P, Maurer H, Vink P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010; 28:744 - 53; http://dx.doi.org/10.1016/j.vaccine.2009.10.064; PMID: 19887137
   PubMed Web of Science ®Google Scholar
• Östergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27:161 - 8; http://dx.doi.org/10.1016/j.vaccine.2008.08.075; PMID: 18834910
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J 2011; 30:e41 - 8; http://dx.doi.org/10.1097/INF.0b013e3182054ab9; PMID: 21200360
   PubMed Web of Science ®Google Scholar
• Bermal N, Huang L-M, Dubey AP, Jain H, Bavdekar A, Lin T-Y, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum Vaccin 2011; 7:239 - 47; http://dx.doi.org/10.4161/hv.7.2.14068; PMID: 21343698
   PubMed Web of Science ®Google Scholar
• Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, Tichmann-Schumann I, Maurer H, Maurer L, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine 2011; 29:4264 - 73; http://dx.doi.org/10.1016/j.vaccine.2011.03.009; PMID: 21420417
   PubMed Web of Science ®Google Scholar
• Memish ZA, Dbaibo G, Montellano M, Verghese VP, Jain H, Dubey AP, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr Infect Dis J 2011; 30:e56 - 62; http://dx.doi.org/10.1097/INF.0b013e31820e6e02; PMID: 21278617
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. Vaccine 2011; 29:4274 - 84; http://dx.doi.org/10.1016/j.vaccine.2011.03.043; PMID: 21443965
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183:160 - 3; http://dx.doi.org/10.1086/317646; PMID: 11078484
   PubMed Web of Science ®Google Scholar
• Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al, The Multilaboratory Study Group. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997; 4:156 - 67; PMID: 9067649
   PubMedGoogle Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780 - 6; PMID: 12965904
   PubMedGoogle Scholar
• Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001; 69:1568 - 73; http://dx.doi.org/10.1128/IAI.69.3.1568-1573.2001; PMID: 11179328
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine 2005; 23:2222 - 7; http://dx.doi.org/10.1016/j.vaccine.2005.01.051; PMID: 15755600
   PubMed Web of Science ®Google Scholar
• Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010; 17:840 - 7; http://dx.doi.org/10.1128/CVI.00529-09; PMID: 20219881
   PubMed Web of Science ®Google Scholar
• Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum Vaccin 2010; 6:881 - 7; http://dx.doi.org/10.4161/hv.6.11.12849; PMID: 21339701
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Findlow H, Waight P, Southern J, Crowley-Luke A, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010; 17:154 - 9; http://dx.doi.org/10.1128/CVI.00384-09; PMID: 19906895
   PubMed Web of Science ®Google Scholar
• Trotter C, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine 2003; 21:1094 - 8; http://dx.doi.org/10.1016/S0264-410X(02)00630-8; PMID: 12559785
   PubMed Web of Science ®Google Scholar
• Trotter CL, Borrow R, Findlow J, Holland A, Frankland S, Andrews NJ, et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol 2008; 15:1694 - 8; http://dx.doi.org/10.1128/CVI.00279-08; PMID: 18827191
   PubMed Web of Science ®Google Scholar
• Trotter CL, Findlow H, Borrow R. Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009. Clin Vaccine Immunol 2012; 19:219 - 22; http://dx.doi.org/10.1128/CVI.05515-11; PMID: 22190393
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Yildirim I, Balmer P, Riley C, Laher G, Andrews N, et al. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005. Vaccine 2007; 25:7233 - 7; http://dx.doi.org/10.1016/j.vaccine.2007.07.019; PMID: 17707957
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853 - 61; http://dx.doi.org/10.1016/S1473-3099(10)70251-6; PMID: 21075057
   PubMed Web of Science ®Google Scholar